The impact of waist-to-hip ratio on clinical outcomes in metastatic breast cancer patients treated with aromatase inhibitors

Breast

Volumn 17, Issue 4, 2008, Pages 418-422

  Artac, Mehmet ^a   Bozcuk, Hakan ^b   Afacan, Berna ^b   Ozdogan, Mustafa ^b   Samur, Mustafa ^b  

^a SELCUK UNIVERSITY   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Aromatase inhibitors; Body fat distribution; Hormonotherapy; Metastatic breast cancer; Waist to hip ratio

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LETROZOLE; TAMOXIFEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY FAT DISTRIBUTION; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; METASTASIS; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; WAIST HIP RATIO;

EID: 48649099153     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2008.01.007     Document Type: Article

References (20)

1. Ali S., and Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2 (2002) 101-112
2. Smith I.E., and Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 348 (2003) 2431-2442
3. Nelson L.R., and Bulun S.E. Estrogen production and action. J Am Acad Dermatol 45 Suppl (2001) S116-S124
4. Longcope C., Baker R., and Johnston Jr. C.C. Androgen and estrogen metabolism: relationship to obesity. Metabolism 35 (1986) 235-237
5. Long J.R., Shu X.O., Cai Q., Wen W., Kataoka N., Gao Y.T., et al. CYP19A1 genetic polymorphisms may be associated with obesity-related phenotypes in Chinese women. Int J Obes (Lond) 31 3 (2007) 418-423
6. Borugian M.J., Sheps S.B., Kim-Sing C., Olivotto I.A., Van Patten C., Dunn B.P., et al. Waist to hip ratio and breast cancer mortality. Am J Epidemiol 158 (2003) 963-968
7. Hollmann M., Runnebaum B., and Gerhard I. Impact of waist-hip-ratio and body-mass-index on hormonal and metabolic parameters in young, obese women. Int J Obes Relat Metab Disord 21 (1997) 476-483
8. Bozcuk H., Uslu G., Samur M., Yildiz M., Ozben T., Ozdoǧan M., et al. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 27 (2004) 58-65
9. Garaulet M., Pérex-Llamas F., Fuente T., Zamora S., and Tebar F.J. Anthropometric, computed tomography and fat cell data in an obese population: relationship with insulin, leptin, tumor necrosis factor-alpha, sex hormone-binding globulin and sex hormones. Eur J Endocrinol 143 5 (2000) 657-666
10. WHO Scientific Group on Research on the Menopause in the 1990s. Research on the menopause in the 1990s: report of a WHO Scientific Group (1996), World Health Organization, Geneva, Switzerland
11. WHO (World Health Organisation). Measuring obesity - classification and description of antropometric data (1988), WHO Regional Office for Europe, Copenhagen EUR/ICP/NUT 125-0612. V
12. Hu F.B. Overweight and obesity in women: health risks and consequences. J Womens Health (Larchmt) 12 (2003) 163-172
13. Carmichael A.R. Obesity as a risk factor for development and poor prognosis of breast cancer. BJOG 113 (2006) 1160-1166
14. Francini G., Petrioli R., Montagnani A., Cadirni A., Campagna S., Francini E., et al. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer 95 2 (2006) 153-158
15. Dignam J.J., Wieand K., Johnson K.A., Fisher B., Xu L., Mamounas E.P., et al. Obesity, tamoxifen use, and outcomes in women with estrogen-receptor-positive early-stage breast cancer. J Natl Cancer Inst 95 (2003) 1467-1476
16. Dowsett M., Martin L.A., Smith I., and Johnston S. Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol 95 (2005) 167-172
17. Chen S., Masri S., Wang X., Phung S., Yuan Y.C., and Wu X. What do we know about the mechanisms of aromatase inhibitor resistance?. J Steroid Biochem Mol Biol 102 (2006) 232-240
18. Gram I.T., Norat T., Rinaldi S., Dossus L., Lukanova A., Téhard B., et al. Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women. Int J Obes (Lond) 30 11 (2006) 1623-1631
19. Sirianni R., Chimento A., Malivindi R., Mazzitelli I., Ando S., and Pezzi V. Insulin-like growth factor-I, regulating aromatase expression through steroidogenic factor 1, supports estrogen-dependent tumor Leydig cell proliferation. Cancer Res 67 17 (2007) 8368-8377
20. Walshe J.M., Denduluri N., and Swain S.M. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24 (2006) 5769-5779